ES2130622T3 - Sistema para la administracion transdermica de farmacos. - Google Patents

Sistema para la administracion transdermica de farmacos.

Info

Publication number
ES2130622T3
ES2130622T3 ES95922554T ES95922554T ES2130622T3 ES 2130622 T3 ES2130622 T3 ES 2130622T3 ES 95922554 T ES95922554 T ES 95922554T ES 95922554 T ES95922554 T ES 95922554T ES 2130622 T3 ES2130622 T3 ES 2130622T3
Authority
ES
Spain
Prior art keywords
therapeutic agent
pct
cyclodextrin
date jan
sec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95922554T
Other languages
English (en)
Inventor
Arto Olavi Urtti
Maria Riitta Sutinen
Timo Petteri Paronen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2130622T3 publication Critical patent/ES2130622T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SISTEMA TRANSDERMICO DE LIBERACION CONTROLADA PARA EL ENVIO DE AL MENOS UN AGENTE TERAPEUTICO QUE INCLUYE: UN RESERVORIO QUE CONTIENE (A) EL AGENTE TERAPEUTICO DE FORMA IONIZADA Y (B) UN AGENTE AJUSTADOR DEL PH QUE CUANDO TOMA AGUA SE CONVIERTE EN UNA SOLUCION AMORTIGUANTE Y (C) UN POLISACARIDO EN FORMA CICLICA SELECCIONADO A PARTIR DE UN GRUPO INTEGRADO POR CICLODEXTRINA, DERIVADOS DE CICLODEXTRINA Y POLIMEROS DE CICLODEXTRINA, EL POLISACARIDO EN FORMA CICLICA ES CAPAZ DE MEJORAR LA SOLUBILIDAD DEL AGENTE TERAPEUTICO EN LA SOLUCION AMORTIGUANTE MEDIANTE LA FORMACION DE UN COMPLEJO DE INCLUSION CON EL AGENTE TERAPEUTICO; Y UNA PARED DEL RESERVORIO QUE INCLUYE UN POLIMERO SUSTANCIALMENTE IMPERMEABLE A LA FORMA IONIZADA O A LA FORMA COMPLEJA DE INCLUSION DEL AGENTE TERAPEUTICO PERO PERMEABLE AL AGUA Y A LA FORMA NO IONIZADA DEL AGENTE TERAPEUTICO. EL SISTEMA PERMITE LA LIBERACION DE UN AGENTE TERAPEUTICO QUE PUEDE SER UN ACIDO DEBIL O UNA BASE DE FORMA QUE MUESTRA MENOS VARIACION ENTRE LOS PACIENTES QUE LOS SISTEMAS YA EXISTENTES.
ES95922554T 1994-07-08 1995-06-20 Sistema para la administracion transdermica de farmacos. Expired - Lifetime ES2130622T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9413866A GB2290964A (en) 1994-07-08 1994-07-08 Transdermal drug delivery system

Publications (1)

Publication Number Publication Date
ES2130622T3 true ES2130622T3 (es) 1999-07-01

Family

ID=10758074

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95922554T Expired - Lifetime ES2130622T3 (es) 1994-07-08 1995-06-20 Sistema para la administracion transdermica de farmacos.

Country Status (12)

Country Link
US (1) US5817332A (es)
EP (1) EP0764020B1 (es)
JP (1) JP3734267B2 (es)
AT (1) ATE178485T1 (es)
AU (1) AU2740595A (es)
CA (1) CA2193129C (es)
DE (1) DE69508938T2 (es)
DK (1) DK0764020T3 (es)
ES (1) ES2130622T3 (es)
GB (1) GB2290964A (es)
GR (1) GR3030369T3 (es)
WO (1) WO1996001626A1 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0838225A3 (en) * 1996-10-25 1999-03-24 Hiji, Yasutake Aqueous local anesthetic solution
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
DE19810951B4 (de) * 1998-03-13 2005-09-29 Ciba Speciality Chemicals Holding Inc. Verwendung eines textilen Materials als transdermales Abgabesystem sowie Verfahren zu seiner Herstellung
DE19814087A1 (de) * 1998-03-30 1999-10-14 Lohmann Therapie Syst Lts Feuchtigkeitsaktivierbares therapeutisches System
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
CN100482216C (zh) * 1999-12-16 2009-04-29 德马全兹股份有限公司 氢氧根释放剂增强透皮渗透的用途
US6719997B2 (en) 2000-06-30 2004-04-13 Dermatrends, Inc. Transdermal administration of pharmacologically active amines using hydroxide-releasing agents as permeation enhancers
US6586000B2 (en) * 1999-12-16 2003-07-01 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
US6582724B2 (en) * 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
US6673363B2 (en) 1999-12-16 2004-01-06 Dermatrends, Inc. Transdermal and topical administration of local anesthetic agents using basic enhancers
US20030104041A1 (en) * 1999-12-16 2003-06-05 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US6689378B1 (en) 1999-12-28 2004-02-10 Kimberly-Clark Worldwide, Inc. Cyclodextrins covalently bound to polysaccharides
US7179483B2 (en) 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US20050233003A1 (en) * 2001-09-28 2005-10-20 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid
US6878693B2 (en) * 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
US20050227911A1 (en) * 2001-09-28 2005-10-13 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules
US7700851B2 (en) * 2001-11-13 2010-04-20 U.S. Smokeless Tobacco Company Tobacco nicotine demethylase genomic clone and uses thereof
JP2005518453A (ja) 2002-02-25 2005-06-23 ディフュージョン・ファーマシューティカルズ・エルエルシー 二極性トランスカロテノイド塩およびそれらの使用
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
ATE372772T1 (de) 2004-07-13 2007-09-15 Schering Oy Retardiertes freigabesystem mit kontrollierter initialabgabe
KR101315904B1 (ko) 2005-02-24 2013-10-08 디퓨젼 파마슈티컬즈 엘엘씨 트랜스 카로티노이드, 이들의 합성, 제제화 및 용도
US8287923B2 (en) * 2005-06-10 2012-10-16 Medical College Of Georgia Research Institute, Inc. Compositions and methods for treating immune disorders
US9446017B2 (en) 2005-08-11 2016-09-20 Augusta University Research Institute, Inc. Compositions and methods for treating herpes simplex virus
BRPI0710674A2 (pt) * 2006-04-07 2011-08-23 Allergan Inc composições incluindo fármacos relativamente insolúveis em água/não umectáveis e métodos para usar as mesmas
US9114133B2 (en) 2006-08-25 2015-08-25 U.S. Dept. Of Veterans Affairs Method of improving diastolic dysfunction
EP2589588A1 (en) 2007-04-13 2013-05-08 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease
CN101878040A (zh) 2007-10-31 2010-11-03 扩散药品有限公司 一类促进小分子扩散的新型治疗剂
US10130689B2 (en) 2009-06-22 2018-11-20 Diffusion Pharmaceuticals Llc Diffusion enhancing compounds and their use alone or with thrombolytics
US20130017188A1 (en) 2009-07-31 2013-01-17 The Brigham And Women's Hospital, Inc. Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
CA2794565C (en) 2010-04-08 2018-08-21 Emory University Substituted androst-4-ene diones
CN103124498A (zh) 2010-06-02 2013-05-29 扩散药品有限公司 双极性反式类胡萝卜素的口服制剂
US9585930B2 (en) 2011-03-20 2017-03-07 Trustees Of Boston University Therapeutic agent for emphysema and COPD
WO2012151474A2 (en) 2011-05-04 2012-11-08 Trustees Of Boston University Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria
WO2013003697A1 (en) 2011-06-30 2013-01-03 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
EP2543370A1 (en) 2011-07-06 2013-01-09 Georgia Health Sciences University Research Institute, Inc. Compositions and Methods for Treating Herpes Simplex Virus
US9243037B2 (en) 2011-11-10 2016-01-26 Trustees Of Boston College Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity
US20150366890A1 (en) 2013-02-25 2015-12-24 Trustees Of Boston University Compositions and methods for treating fungal infections
EP3036226B1 (en) 2013-08-22 2020-01-08 The General Hospital Corporation Inhibitors of human 12/15-lipoxygenase
US11382883B2 (en) 2013-08-29 2022-07-12 Trustees Of Boston University Intermediate metabolism products to potentiate aminoglycoside antibiotics in bacterial infections
RU2018105761A (ru) 2013-10-07 2019-02-26 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Устройства для трансдермальной доставки дексмедетомидина и способы их применения
TWI709417B (zh) * 2013-10-07 2020-11-11 美商帝國製藥美國股份有限公司 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物
RU2648449C2 (ru) 2013-10-07 2018-03-26 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Способы и композиции для трансдермальной доставки неседативного количества дексмедетомидина
CN110604728A (zh) * 2013-10-07 2019-12-24 帝国制药美国公司 用于管理疼痛的包含右旋美托咪啶经皮组合物的方法及组合物
EP3087985B1 (en) 2013-12-18 2018-10-17 Maruishi Pharmaceutical Co., Ltd. Hydrous adhesive patch
JP2017501224A (ja) * 2013-12-18 2017-01-12 ジー・エヌ・ティー・エル・エル・シー 緑内障の治療用組成物及び方法
EP3303286B1 (en) 2015-06-01 2023-10-04 Cedars-Sinai Medical Center Compounds that bind to rela of nf-kb for use in treating cancer
KR102123365B1 (ko) 2015-07-28 2020-06-16 바이옴 테라퓨틱스 리미티드 항박테리아 치료제 및 예방제
US10493049B2 (en) 2016-02-10 2019-12-03 Niracle LLC Applicator-based transdermal drug delivery system for administration of drugs in combination with topical formulations
EP3432929A4 (en) 2016-03-24 2019-11-27 Diffusion Pharmaceuticals LLC USE OF BIPOLAR TRANSCAROTINOIDS WITH CHEMOTHERAPY AND RADIOTHERAPY FOR THE TREATMENT OF CANCER
KR20210113439A (ko) 2016-10-31 2021-09-15 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치를 이용한 통증을 관리하는 방법
SG10202107367SA (en) 2016-12-31 2021-08-30 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
ES3004544T3 (en) 2018-06-27 2025-03-12 Bioxcel Therapeutics Inc Film formulations containing dexmedetomidine and methods of producing them
TWI772807B (zh) 2019-05-27 2022-08-01 日商救急藥品工業股份有限公司 外用製劑
US20240024288A1 (en) 2019-07-19 2024-01-25 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
JP2024540701A (ja) 2021-11-08 2024-11-01 リー・ウェイヨン 患者に薬物を送達するための経皮薬物送達システム
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4756710A (en) * 1985-04-05 1988-07-12 Merck & Co., Inc. pH-Mediated drug delivery system
EP0241806A1 (en) * 1986-04-14 1987-10-21 Fujisawa Pharmaceutical Co., Ltd. Sustained-release transdermal delivery preparations
US4781924A (en) * 1987-11-09 1988-11-01 Alza Corporation Transdermal drug delivery device
SE8904296D0 (sv) * 1989-12-21 1989-12-21 Pharmacia Ab Transdermal system
HU210921B (en) * 1990-03-28 1995-09-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them
GB9012663D0 (en) * 1990-06-07 1990-08-01 Erba Carlo Spa Galenic formulations containing cyclodextrins
GB9111732D0 (en) * 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
WO1993007858A1 (en) * 1991-10-16 1993-04-29 Arto Olavi Urtti Peroral drug delivery system
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation

Also Published As

Publication number Publication date
JP3734267B2 (ja) 2006-01-11
EP0764020A1 (en) 1997-03-26
GB9413866D0 (en) 1994-08-24
EP0764020B1 (en) 1999-04-07
AU2740595A (en) 1996-02-09
WO1996001626A1 (en) 1996-01-25
DK0764020T3 (da) 1999-10-18
DE69508938T2 (de) 1999-09-16
DE69508938D1 (de) 1999-05-12
GR3030369T3 (en) 1999-09-30
CA2193129C (en) 2007-11-06
GB2290964A (en) 1996-01-17
CA2193129A1 (en) 1996-01-25
US5817332A (en) 1998-10-06
JPH10502388A (ja) 1998-03-03
ATE178485T1 (de) 1999-04-15

Similar Documents

Publication Publication Date Title
ATE178485T1 (de) Transdermales arzneistoff-abgabesystem
ES2569949T3 (es) Formulaciones farmacéuticas que comprenden un péptido complejado con una dicetopiperazina
ATE267798T1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
ATE198152T1 (de) Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe
TR200001998T1 (tr) Kontrollü salıverilen tolterodin uygulamak için ilaç formülasyonu
ATE298259T1 (de) Vorrichtung zur lokalen verabreichung einer arznei in einer körperhöhle
SE9503143D0 (sv) New preparation
ES2164040T1 (es) Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos.
ID28160A (id) Sistem pengobatan untuk pemberian fenilasetilglutamina, fenilasetilisoglutamina dan/atau fenilasetat.
ATE237330T1 (de) Verabreichung von nikotin im dickdarm zur behandlung von entzündlicher eingeweidenerkrankung
SE8703034L (sv) Oralt terapeutiskt system med systemisk verkan
ES2117642T3 (es) Preparado farmaceutico que contiene n-glicofuroles y n-etilen glicoles.
JPH0578241A (ja) ケトプロフエンリジン塩を含む局所用親水性医薬組成物
ATE146677T1 (de) Pharmazeutische formulierung zur behandlung der nicotinabhängigkeit
SG146638A1 (en) Pharmaceutical delivery system
EP0838225A3 (en) Aqueous local anesthetic solution
AU5673399A (en) Compositions and methods for treating intracellular infections
DK0856312T3 (da) Anvendelse af trospiumchlorid til fremstilling af et lægemiddel til behandling af blæresygdomme
CO5640120A2 (es) Formulacion y metodods para el tratamiento de trombocitemia
ATE135203T1 (de) System zur peroralen arzneimittelabgabe
PT873134E (pt) Formulacao aquosa de libertacao prolongada compreendendo factor de libertacao da hormona do crescimento bovino
BR0009676A (pt) Método para o tratamento e/ou profilaxia de malária, usos de atovaquona e de uma combinação de atovaquona, proguanila e primaquina, combinação de atovaquona, proguanila e primaquina, kit, e, formulação farmacêutica
AR005724A1 (es) Derivados de ureido biologicamente activos utiles en el tratamiento de esclerosis multiple
SE9700617D0 (sv) New composition
FR2809958B1 (fr) Composition pharmaceutique sous forme liquide destinee a l'administration par voie orale d'un principe actif, ayant un gout desagreable, notamment un gout amer

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 764020

Country of ref document: ES